A systematic review and meta-analysis of 23 studies and 547 patients finds that CD19-directed CAR T-cell therapy delivers ...
A pharmacovigilance analysis of nearly five million adverse-event reports finds that liver injury after CAR T-cell therapy is ...
The hope with CAR T cell therapies for autoimmune disease is that they can reset the immune system and induce deep remission. But recent trial pauses have renewed concerns about safety, patient ...
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. We ...
HLA sensitization poses a major challenge to kidney transplantation for patients with end-stage kidney disease, especially for highly sensitized candidates. Attempts at antibody elimination ...
Dublin, Oct. 19, 2026 (GLOBE NEWSWIRE) -- "Engineered T Cells Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Engineered T Cells Market research report ...
In-depth insights into CRISPR, CAR-T and TCR-T innovations, with analysis by cell type, product, disease, end-use and regionDublin, Oct. 19, 2026 (GLOBE NEWSWIRE) -- "Immune Cell Engineering Market ...
UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple ...
LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a ...
WAYPOINT will help patients track and manage side effects from home during the critical 60 days after treatment, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results